Drugs / TT-034
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01899092 | Jan 2014 → Sep 2016 | chronic hepatitis C virus infection | Tacere Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TT-034 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01899092 ↗ |
| Action | Inhibit | “The anti-HCV sequences will be comprised of three different short hairpin RNAs (shRNA) that have the ability to directly cleave the RNA genome of HCV by a process known as RNA...” NCT01899092 ↗ |
| Route | Intravenous | “The study drug will be given as a single dose IV infusion on Day 1.” NCT01899092 ↗ |